<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929615</url>
  </required_header>
  <id_info>
    <org_study_id>v1.0-20150805</org_study_id>
    <nct_id>NCT02929615</nct_id>
  </id_info>
  <brief_title>Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to research the standard and individualized treatment model for
      relapse and refractory lymphatic system malignant tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>2 years after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>complete response</measure>
    <time_frame>2 years after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years after treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with relapse and refractory lymphoma and multiple myeloma.

          2. At least 1 measurable lesions and its size≥15mm.

          3. Patients ≤65 years，no limitations for both gender.

          4. ECOG score is 0-1.

          5. Life expectancy≥3 months.

          6. LVEF≥ 55%; Peripheral blood: WBC ≥ 3.5×10(9)/L,neutrophil ≥1.5×10(9)/L,
             PLT≥75×109/L，Hb≥90g/L; Renal function: Cr≤2.0×UNL; Liver function:
             BIL≤2.0×UNL，ALT/AST≤2.5×UNL;

          7. Written informed consent are acquired.

        Exclusion Criteria:

          1. Previously received stem cell transplantation.

          2. Women with pregnant, lactating or not to take contraceptive measures.

          3. Severe acute infection or suppurative and chronic infection that wound not healing.

          4. Severe heart failure.

          5. Suffering from mental disorders and poor compliance.

          6. Other situations that investigators consider as contra-indication for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhu Jun, archiater</last_name>
    <phone>010-88196596</phone>
    <email>Zhujun@csco.org</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhu Jun, archiater</last_name>
      <phone>010-88196596</phone>
      <email>Zhujun@csco.org</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2016</study_first_submitted>
  <study_first_submitted_qc>October 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2016</study_first_posted>
  <last_update_submitted>October 10, 2016</last_update_submitted>
  <last_update_submitted_qc>October 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Jun Zhu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

